Cargando…
Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double‐blind, placebo‐controlled, randomized clinical trial
BACKGROUND: Information regarding the efficacy of telmisartan for feline systemic arterial hypertension is limited. OBJECTIVES: To evaluate the safety and efficacy of PO administered telmisartan solution in hypertensive cats. ANIMALS: Client‐owned cats with indirect systolic arterial blood pressure...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430933/ https://www.ncbi.nlm.nih.gov/pubmed/30851066 http://dx.doi.org/10.1111/jvim.15429 |
_version_ | 1783405850674593792 |
---|---|
author | Coleman, Amanda E. Brown, Scott A. Traas, Anne M. Bryson, Lawrence Zimmering, Tanja Zimmerman, Alicia |
author_facet | Coleman, Amanda E. Brown, Scott A. Traas, Anne M. Bryson, Lawrence Zimmering, Tanja Zimmerman, Alicia |
author_sort | Coleman, Amanda E. |
collection | PubMed |
description | BACKGROUND: Information regarding the efficacy of telmisartan for feline systemic arterial hypertension is limited. OBJECTIVES: To evaluate the safety and efficacy of PO administered telmisartan solution in hypertensive cats. ANIMALS: Client‐owned cats with indirect systolic arterial blood pressure (SBP) of 160‐200 mm Hg, based on multiple measurements. METHODS: This multicenter trial consisted a 28‐day, prospective, randomized, double‐blind, placebo‐controlled, parallel group, efficacy phase and a 154‐day extended‐use telmisartan phase. Hypertensive cats were randomly assigned to receive 1.5 mg telmisartan/kg PO q12h for 14 days, followed by 2 mg telmisartan/kg PO q24h, or equivalent volume of placebo. Systolic blood pressure was measured on days 0, 14, and 28. Change in SBP compared to baseline was calculated for days 14 and 28. Telmisartan efficacy was defined as significant decrease in SBP at day 14 compared to placebo and a clinically relevant (>20 mm Hg) decrease in SBP at day 28. RESULTS: Two‐hundred twenty‐one cats were included. On day 14, least squares mean (95% confidence interval) SBP decrease was significantly larger in telmisartan‐treated (−23.3 mm Hg [−28.2 to −18.3]) versus placebo‐treated (−7.5 mm Hg [−13.6 to −1.5]) cats (P = .0005). On day 28, telmisartan treatment resulted in a clinically relevant SBP decrease (−23.9 mm Hg [−27.8 to −20.0]), whereas placebo did not (−11.6 mm Hg [−17.4 to −5.9 mm Hg]). The decrease in SBP persisted over the 6‐month trial in telmisartan‐treated cats. CONCLUSIONS AND CLINICAL IMPORTANCE: Telmisartan significantly decreased SBP to a clinically relevant extent and was well tolerated in hypertensive cats. |
format | Online Article Text |
id | pubmed-6430933 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64309332019-04-04 Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double‐blind, placebo‐controlled, randomized clinical trial Coleman, Amanda E. Brown, Scott A. Traas, Anne M. Bryson, Lawrence Zimmering, Tanja Zimmerman, Alicia J Vet Intern Med SMALL ANIMAL BACKGROUND: Information regarding the efficacy of telmisartan for feline systemic arterial hypertension is limited. OBJECTIVES: To evaluate the safety and efficacy of PO administered telmisartan solution in hypertensive cats. ANIMALS: Client‐owned cats with indirect systolic arterial blood pressure (SBP) of 160‐200 mm Hg, based on multiple measurements. METHODS: This multicenter trial consisted a 28‐day, prospective, randomized, double‐blind, placebo‐controlled, parallel group, efficacy phase and a 154‐day extended‐use telmisartan phase. Hypertensive cats were randomly assigned to receive 1.5 mg telmisartan/kg PO q12h for 14 days, followed by 2 mg telmisartan/kg PO q24h, or equivalent volume of placebo. Systolic blood pressure was measured on days 0, 14, and 28. Change in SBP compared to baseline was calculated for days 14 and 28. Telmisartan efficacy was defined as significant decrease in SBP at day 14 compared to placebo and a clinically relevant (>20 mm Hg) decrease in SBP at day 28. RESULTS: Two‐hundred twenty‐one cats were included. On day 14, least squares mean (95% confidence interval) SBP decrease was significantly larger in telmisartan‐treated (−23.3 mm Hg [−28.2 to −18.3]) versus placebo‐treated (−7.5 mm Hg [−13.6 to −1.5]) cats (P = .0005). On day 28, telmisartan treatment resulted in a clinically relevant SBP decrease (−23.9 mm Hg [−27.8 to −20.0]), whereas placebo did not (−11.6 mm Hg [−17.4 to −5.9 mm Hg]). The decrease in SBP persisted over the 6‐month trial in telmisartan‐treated cats. CONCLUSIONS AND CLINICAL IMPORTANCE: Telmisartan significantly decreased SBP to a clinically relevant extent and was well tolerated in hypertensive cats. John Wiley & Sons, Inc. 2019-03-09 2019 /pmc/articles/PMC6430933/ /pubmed/30851066 http://dx.doi.org/10.1111/jvim.15429 Text en © 2019 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | SMALL ANIMAL Coleman, Amanda E. Brown, Scott A. Traas, Anne M. Bryson, Lawrence Zimmering, Tanja Zimmerman, Alicia Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double‐blind, placebo‐controlled, randomized clinical trial |
title | Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double‐blind, placebo‐controlled, randomized clinical trial |
title_full | Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double‐blind, placebo‐controlled, randomized clinical trial |
title_fullStr | Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double‐blind, placebo‐controlled, randomized clinical trial |
title_full_unstemmed | Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double‐blind, placebo‐controlled, randomized clinical trial |
title_short | Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double‐blind, placebo‐controlled, randomized clinical trial |
title_sort | safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: results of a double‐blind, placebo‐controlled, randomized clinical trial |
topic | SMALL ANIMAL |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430933/ https://www.ncbi.nlm.nih.gov/pubmed/30851066 http://dx.doi.org/10.1111/jvim.15429 |
work_keys_str_mv | AT colemanamandae safetyandefficacyoforallyadministeredtelmisartanforthetreatmentofsystemichypertensionincatsresultsofadoubleblindplacebocontrolledrandomizedclinicaltrial AT brownscotta safetyandefficacyoforallyadministeredtelmisartanforthetreatmentofsystemichypertensionincatsresultsofadoubleblindplacebocontrolledrandomizedclinicaltrial AT traasannem safetyandefficacyoforallyadministeredtelmisartanforthetreatmentofsystemichypertensionincatsresultsofadoubleblindplacebocontrolledrandomizedclinicaltrial AT brysonlawrence safetyandefficacyoforallyadministeredtelmisartanforthetreatmentofsystemichypertensionincatsresultsofadoubleblindplacebocontrolledrandomizedclinicaltrial AT zimmeringtanja safetyandefficacyoforallyadministeredtelmisartanforthetreatmentofsystemichypertensionincatsresultsofadoubleblindplacebocontrolledrandomizedclinicaltrial AT zimmermanalicia safetyandefficacyoforallyadministeredtelmisartanforthetreatmentofsystemichypertensionincatsresultsofadoubleblindplacebocontrolledrandomizedclinicaltrial |